Epigenetic Modifications as Biomarkers of Tumor Development
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 139
Special Issue Editor
Interests: multi-omics; bioinformatics; AI; cancer biology; immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Understanding of epigenomics revolutionizes the way of screening, diagnosing and treating cancers. Unlike static genetic mutations, epigenetic alterations, including DNA methylation, histone modifications and non-coding RNA dysregulation, offer a dynamic and potentially reversible biomarker of oncogenesis. This Special Issue aims to bridge the gap between basic molecular research and clinical application. We invite original research and comprehensive reviews that explore the identification, validation and implementation of epigenetic signatures as robust biomarkers for cancer screening, early diagnosis and monitoring. By focusing on early detection, therapeutic monitoring and the prediction of treatment response, this collection seeks to highlight how the epigentics can redefine diagnostic accuracy and patient outcomes in modern cancer care.
Dr. Chenkai Ma
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DNA Methylation
- histone acetylation
- liquid biopsies
- oncogenesis
- chromatin remodeling
- early detection biomarkers
- precision oncology
- pharmaco-epigenetics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
